A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
| Title: | A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results |
|---|---|
| Authors: | Desai, JayeshAff1, IDs00280025048091_cor1; Deva, SanjeevAff2; Gao, BoAff3; Yang, KunyuAff4; O’Byrne, Kenneth J.Aff5; Sun, MeiliAff6, Aff7; Liu, TianshuAff8; Meniawy, TarekAff9, Aff10; Yu, XinminAff11; Voskoboynik, MarkAff12, Aff13; Davar, DiwakarAff14; Matos, MarcoAff15, Aff16, Aff17, Aff18; Leaw, ShiangjiinAff19; Rahman, TahminaAff20; Qu, XiaofeiAff19; Giovinazzo, HughAff20; Chen, XinAff21; Dong, YanAff22; Day, DaphneAff23, Aff24 |
| Source: | Cancer Chemotherapy and Pharmacology. 95(1) |
| Database: | Springer Nature Journals |